代谢组学在眼部疾病中的研究进展

doi:10.3980/j.issn.1672-5123.2024.3.17

首页 > 过刊浏览>2024年第24卷第3期 >2024,24(3):420-426. DOI:10.3980/j.issn.1672-5123.2024.3.17

代谢组学在眼部疾病中的研究进展

蒋佳璇
蒋佳璇
中国江苏省南京市,南京大学医学院附属鼓楼医院眼科
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
刘俊鹏
刘俊鹏
中国江苏省南京市,南京大学医学院附属鼓楼医院眼科
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
欧阳珺雯
欧阳珺雯
中国江苏省南京市,南京大学医学院附属鼓楼医院眼科
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
张成晓
张成晓
中国江苏省南京市,南京大学医学院附属鼓楼医院眼科
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
胡凯
胡凯
中国江苏省南京市,南京大学医学院附属鼓楼医院眼科
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

Advances of metabolomics in ocular diseases

Jiang Jiaxuan
Jiang Jiaxuan
Department of Ophthalmology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu Province, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
Liu Junpeng
Liu Junpeng
Department of Ophthalmology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu Province, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
Ouyang Junwen
Ouyang Junwen
Department of Ophthalmology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu Province, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
Zhang Chengxiao
Zhang Chengxiao
Department of Ophthalmology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu Province, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
Hu Kai
Hu Kai
Department of Ophthalmology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu Province, China
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

发布日期：2024-02-23

摘要
图/表
访问统计
PDF预览
参考文献
相似文献
引证文献
附件

[关键词]

代谢组学 ; 眼部疾病 ; 糖尿病视网膜病变 ; 年龄相关性黄斑变性 ; 青光眼

[摘要]

眼部疾病是全球的重要健康问题。代谢组学是对一个系统中的代谢物进行识别和定量的新兴研究技术，可用于阐明疾病机制及识别新的生物标志物，为深入探究眼部疾病的发生和发展提供了新的策略。本文简介了代谢组学的基本技术，汇总分析了代谢组学在糖尿病视网膜病变、年龄相关性黄斑变性、青光眼和干眼四种眼部疾病中的最新研究进展，总结了潜在的生物标志物和代谢途径，并对代谢组学在未来眼部疾病管理和治疗中的应用前景进行了展望。

[Key word]

metabolomics ; ocular diseases ; diabetic retinopathy ; age-related macular degeneration ; glaucoma

[Abstract]

Ocular diseases pose a significant challenge to global health. The field of metabolomics, which involves the systematic identification and quantification of metabolites within a biological system, has emerged as a promising research approach for unraveling disease mechanisms and discovering novel biomarkers. Through its application, metabolomics has yielded valuable knowledge pertaining to the initiation and advancement of various ocular diseases. This review presents an overview of metabolomics and examines recent research progess in four ocular diseases, specifically diabetic retinopathy, age-related macular degeneration, glaucoma, and dry eye, summarizing potential biomarkers and metabolic pathways associated with these diseases. Additionally, this review offers insights into the future prospects of utilizing metabolomics for the management and treatment of ocular diseases.

[中图分类号]

[基金项目]

江苏省自然科学基金(No.BK20201114); 南京鼓楼医院临床专项(No.2022-LCYJ-MS-36)

引用本文 / Get Citation

蒋佳璇,刘俊鹏,欧阳珺雯,等.代谢组学在眼部疾病中的研究进展.国际眼科杂志, 2024,24(3):420-426.

分享 / Share

文章指标 / Article Metrics

点击次数: 266

下载次数: 1156

Html阅读次数: 0

引用次数: 0

历史 / History

收稿日期: 2023-09-27

最后修改日期: 2024-01-17

在线发布日期: 2024-02-23

\〖1\〗 Rinschen MM, Ivanisevic J, Giera M, et al. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol, 2019,20(6):353-367.

\〖2\〗 Babu M, Snyder M. Multi-omics profiling for health. Mol Cell Proteom, 2023,22(6):100561.

\〖3\〗 Nazifova-Tasinova N, Radeva M, Galunska B, et al. Metabolomic analysis in ophthalmology. Biomed Pap, 2020,164(3):236-246.

\〖4\〗 Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol, 2016,17(7):451-459.

\〖5\〗 Wishart DS. Metabolomics for investigating physiological and pathophysiological processes. Physiol Rev, 2019,99(4):1819-1875.

\〖6\〗 Alseekh S, Aharoni A, Brotman Y, et al. Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices. Nat Methods, 2021,18(7):747-756.

\〖7\〗 Luo Y. Metabolomics and biomarkers in ocular matrix: beyond ocular diseases. Int J Ophthalmol, 2020,13(6):991-1003.

\〖8\〗 2019 Blindness and Vision Impairment Collaborators GBD, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020:the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health, 2021,9(2):e144-e160.

\〖9\〗 Barba I, Garcia-Ramírez M, Hernández C, et al. Metabolic fingerprints of proliferative diabetic retinopathy: An¹H-NMR-based metabonomic approach using vitreous humor. Invest Ophthalmol Vis Sci, 2010,51(9):4416-4421.

\〖10\〗 Haines NR, Manoharan N, Olson JL, et al. Metabolomics analysis of human vitreous in diabetic retinopathy and rhegmatogenous retinal detachment. J Proteome Res, 2018,17(7):2421-2427.

\〖11\〗 Chen LY, Cheng CY, Choi H, et al. Plasma metabonomic profiling of diabetic retinopathy. Diabetes, 2016,65(4):1099-1108.

\〖12\〗 Xia JF, Wang ZH, Liang QL, et al. Correlations of six related pyrimidine metabolites and diabetic retinopathy in Chinese type 2 diabetic patients. Clin Chim Acta, 2011,412(11-12):940-945.

\〖13\〗 Xia JF, Wang ZH, Zhang FF. Association between related purine metabolites and diabetic retinopathy in type 2 diabetic patients. Int J Endocrinol, 2014,2014:651050.

\〖14\〗 Schwartzman ML, Iserovich P, Gotlinger K, et al. Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy. Diabetes, 2010,59(7):1780-1788.

\〖15\〗 Al-Shabrawey M, Mussell R, Kahook K, et al. Increased expression and activity of 12-lipoxygenase in oxygen-induced ischemic retinopathy and proliferative diabetic retinopathy: implications in retinal neovascularization. Diabetes 2011; 60:614-624.

\〖16\〗 Lin AL, Roman RJ, Regan KA, et al. Eicosanoid profiles in the vitreous humor of patients with proliferative diabetic retinopathy. Int J Mol Sci, 2020,21(20):7451.

\〖17\〗 Zhao TT, Wang YB, Guo XJ, et al. Altered oxylipin levels in human vitreous indicate imbalance in pro-/ anti-inflammatory homeostasis in proliferative diabetic retinopathy. Exp Eye Res, 2022,214:108799.

\〖18\〗 Wang ZY, Tang JY, Jin EZ, et al. Metabolomic comparison followed by cross-validation of enzyme-linked immunosorbent assay to reveal potential biomarkers of diabetic retinopathy in Chinese with type 2 diabetes. Front Endocrinol, 2022,13:986303.

\〖19\〗 Paris LP, Johnson CH, Aguilar E, et al. Global metabolomics reveals metabolic dysregulation in ischemic retinopathy. Metabolomics, 2015,12(1):15.

\〖20\〗 Sumarriva K, Uppal K, Ma CY, et al. Arginine and carnitine metabolites are altered in diabetic retinopathy. Invest Ophthalmol Vis Sci, 2019,60(8):3119.

\〖21\〗 Peters KS, Rivera E, Warden C, et al. Plasma arginine and citrulline are elevated in diabetic retinopathy. Am J Ophthalmol, 2022,235:154-162.

\〖22\〗 Tomita Y, Cagnone G, Fu ZJ, et al. Vitreous metabolomics profiling of proliferative diabetic retinopathy. Diabetologia, 2021,64(1):70-82.

\〖23\〗 Sun Y, Kong L, Zhang AH, et al. A hypothesis from metabolomics analysis of diabetic retinopathy: arginine-creatine metabolic pathway may be a new treatment strategy for diabetic retinopathy. Front Endocrinol, 2022,13:858012.

\〖24\〗 Rhee SY, Jung ES, Park HM, et al. Plasma glutamine and glutamic acid are potential biomarkers for predicting diabetic retinopathy. Metabolomics, 2018,14(7):89.

\〖25\〗 Jin HY, Zhu BJ, Liu X, et al. Metabolic characterization of diabetic retinopathy: an ¹H-NMR-based metabolomic approach using human aqueous humor. J Pharm Biomed Anal, 2019,174:414-421.

\〖26\〗 Ding C, Wang N, Wang ZC, et al. Integrated analysis of metabolomics and lipidomics in plasma of T2DM patients with diabetic retinopathy. Pharmaceutics, 2022,14(12):2751.

\〖27\〗 Wang HY, Li S, Wang C, et al. Plasma and vitreous metabolomics profiling of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci, 2022,63(2):17.

\〖28\〗 Apte RS. Age-related macular degeneration. N Engl J Med, 2021,385(6):539-547.

\〖29\〗 Lin JB, Halawa OA, Husain D, et al. Dyslipidemia in age-related macular degeneration. Eye, 2022,36(2):312-318.

\〖30\〗 Han GG, Wei PH, He MQ, et al. Glucose metabolic characterization of human aqueous humor in relation to wet age-related macular degeneration. Invest Ophthalmol Vis Sci, 2020,61(3):49.

\〖31\〗 Han GG, Wei PH, He MQ, et al. Metabolomic profiling of the aqueous humor in patients with wet age-related macular degeneration using UHPLC-MS/MS. J Proteome Res, 2020,19(6):2358-2366.

\〖32\〗 Liu K, Fang JW, Jin J, et al. Serum metabolomics reveals personalized metabolic patterns for macular neovascular disease patient stratification. J Proteome Res, 2020,19(2):699-707.

\〖33\〗 Ren JB, Ren AL, Deng XZ, et al. Long-chain polyunsaturated fatty acids and their metabolites regulate inflammation in age-related macular degeneration. J Inflamm Res, 2022,15:865-880.

\〖34\〗 Laíns I, Gantner M, Murinello S, et al. Metabolomics in the study of retinal health and disease. Prog Retin Eye Res, 2019,69:57-79.

\〖35\〗 Kang QZ, Yang CX. Oxidative stress and diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol, 2020,37:101799.

\〖36\〗 Chao de la Barca JM, Rondet-Courbis B, Ferré M, et al. A plasma metabolomic profiling of exudative age-related macular degeneration showing carnosine and mitochondrial deficiencies. J Clin Med, 2020,9(3):631.

\〖37\〗 Mitchell SL, Ma CY, Scott WK, et al. Plasma metabolomics of intermediate and neovascular age-related macular degeneration patients. Cells, 2021,10(11):3141.

\〖38\〗 Mitchell SL, Uppal K, Williamson SM, et al. The carnitine shuttle pathway is altered in patients with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci, 2018,59(12):4978-4985.

\〖39\〗 Deng YH, Shuai P, Wang HX, et al. Untargeted metabolomics for uncovering plasma biological markers of wet age-related macular degeneration. Aging, 2021,13(10):13968-14000.

\〖40\〗 Acar IE, Lores-Motta L, Colijn JM, et al. Integrating Metabolomics, Genomics, and Disease Pathways in Age-Related Macular Degeneration: The EYE-RISK Consortium. Ophthalmology, 2020, 127:1693-1709.

\〖41\〗 Osborn MP, Park Y, Parks MB, et al. Metabolome-wide association study of neovascular age-related macular degeneration. PLoS One, 2013,8(8):e72737.

\〖42\〗 Luo D, Deng TT, Yuan W, et al. Plasma metabolomic study in Chinese patients with wet age-related macular degeneration. BMC Ophthalmol, 2017,17(1):165.

\〖43\〗 Lains I, Mendez K, Nigalye A, et al. Plasma metabolomic profiles associated with three-year progression of age-related macular degeneration. Metabolites, 2022,12(1):32.

\〖44\〗 Mendez KM, Kim J, Laíns I, et al. Association of human plasma metabolomics with delayed dark adaptation in age-related macular degeneration. Metabolites, 2021,11(3):183.

\〖45\〗 May C, Reinehr S. The pathology behind glaucoma: what we already know using omics technologies. Neural Regen Res, 2023,18(12):2701-2702.

\〖46\〗 Agudo-Barriuso M, Lahoz A, Nadal-Nicolás FM, et al. Metabolomic changes in the rat retina after optic nerve crush. Invest Ophthalmol Vis Sci, 2013,54(6):4249.

\〖47\〗 Mayordomo-Febrer A, López-Murcia M, Morales-Tatay JM, et al. Metabolomics of the aqueous humor in the rat glaucoma model induced by a series of intracamerular sodium hyaluronate injection. Exp Eye Res, 2015,131:84-92.

\〖48\〗 Pan CW, Ke C, Chen Q, et al. Differential metabolic markers associated with primary open-angle glaucoma and cataract in human aqueous humor. BMC Ophthalmol, 2020,20:183.

\〖49\〗 Buisset A, Gohier P, Leruez S, et al. Metabolomic profiling of aqueous humor in glaucoma points to taurine and spermine deficiency: findings from the eye-D study. J Proteome Res, 2019,18(3):1307-1315.

\〖50\〗 Burgess LG, Uppal K, Walker DI, et al. Metabolome-wide association study of primary open angle glaucoma. Invest Ophthalmol Vis Sci, 2015,56(8):5020-5028.

\〖51\〗 Nusinovici S, Li HT, Thakur S, et al. High-density lipoprotein 3 cholesterol and primary open-angle glaucoma. Ophthalmology, 2022,129(3):285-294.

\〖52\〗 Leruez S, Marill A, Bresson T, et al. A metabolomics profiling of glaucoma points to mitochondrial dysfunction, senescence, and polyamines deficiency. Invest Ophthalmol Vis Sci, 2018,59(11):4355-4361.

\〖53\〗 Kouassi Nzoughet J, Guehlouz K, Leruez S, et al. A data mining metabolomics exploration of glaucoma. Metabolites, 2020,10(2):49.

\〖54\〗 Javadiyan S, Burdon KP, Whiting MJ, et al. Elevation of serum asymmetrical and symmetrical dimethylarginine in patients with advanced glaucoma. Invest Ophthalmol Vis Sci, 2012,53(4):1923-1927.

\〖55\〗 Garhöfer G, Schmetterer L. Nitric oxide: a drug target for glaucoma revisited. Drug Discov Today, 2019,24(8):1614-1620.

\〖56\〗 Tang YZ, Pan YQ, Chen YH, et al. Metabolomic profiling of aqueous humor and plasma in primary open angle glaucoma patients points towards novel diagnostic and therapeutic strategy. Front Pharmacol, 2021,12:621146.

\〖57\〗 Rong SZ, Li Y, Guan Y, et al. Long-chain unsaturated fatty acids as possible important metabolites for primary angle-closure glaucoma based on targeted metabolomic analysis. Biomed Chromatogr, 2017,31(9).

\〖58\〗黄悦, 李妍, 包郑伊琳, 等. 假性剥脱性青光眼的生物标志物研究进展. 国际眼科杂志, 2023,23(7):1134-1138.

\〖59\〗 Akpek EK, Amescua G, Farid M, et al. Dry eye syndrome preferred practice pattern^®. Ophthalmology, 2019,126(1):286-334.

\〖60\〗 Yazdani M, Elgstøen KBP, Rootwelt H, et al. Tear metabolomics in dry eye disease: a review. Int J Mol Sci, 2019,20(15):3755.

\〖61\〗 Lam SM, Tong L, Reux B, et al. Lipidomic analysis of human tear fluid reveals structure-specific lipid alterations in dry eye syndrome 1. J Lipid Res, 2014,55(2):299-306.

\〖62\〗 Pieragostino D, Agnifili L, Cicalini I, et al. Tear film steroid profiling in dry eye disease by liquid chromatography tandem mass spectrometry. Int J Mol Sci, 2017,18(7):1349.

\〖63\〗 Vehof J, Hysi PG, Hammond CJ. A metabolome-wide study of dry eye disease reveals serum androgens as biomarkers. Ophthalmology, 2017,124(4):505-511.

\〖64\〗 Dietrich J, Garreis F, Paulsen F. Pathophysiology of meibomian glands-an overview. Ocul Immunol Inflamm, 2021,29(4):803-810.

\〖65\〗 Wang LX, Deng YP. The applications of androgen in the treatment of dry eye disease: a systematic review of clinical studies. Endocr J, 2020,67(9):893-902.

\〖66\〗 Galbis-Estrada C, Martinez-Castillo S, Morales JM, et al. Differential effects of dry eye disorders on metabolomic profile by 1H nuclear magnetic resonance spectroscopy. Biomed Res Int, 2014,2014:542549.

\〖67\〗 Lee JD, Kim HY, Park JJ, et al. Metabolomics approach to biomarkers of dry eye disease using ¹H-NMR in rats. J Toxicol Environ Health Part A, 2021,84(8):313-330.

\〖68\〗 Chen XL, Rao J, Zheng Z, et al. Integrated tear proteome and metabolome reveal panels of inflammatory-related molecules via key regulatory pathways in dry eye syndrome. J Proteome Res, 2019,18(5):2321-2330.